Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:

NCT ID: NCT01285596 Completed - Healthy Volunteers Clinical Trials

A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex

Start date: March 2009
Phase: Phase 1
Study type: Interventional

Young and elderly, male and female subjects are each given 2 different doses of mirabegron for 7 days each. Levels of mirabegron in the blood are assessed.

NCT ID: NCT01284868 Completed - Healthy Volunteers Clinical Trials

A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.

Start date: July 2009
Phase: Phase 1
Study type: Interventional

To explore what is driving heart-rate increases after dosing with mirabegron. Subjects will be given a beta-blocker at the same time as mirabegron.

NCT ID: NCT01280175 Completed - Healthy Volunteers Clinical Trials

Foster With or Without Charcoal Block or Aerochamber Plus

Start date: December 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the systemic exposure of BDP, its metabolite beclomethasone 17-monopropionate (B17MP) and formoterol after inhalation of BDP/Formoterol 100/6 µg pMDI combination (CHF1535) using the standard actuator and charcoal block technique or using a Spacer (AeroChamber Plus, Trudell) in comparison with inhalation using the standard actuator

NCT ID: NCT01277718 Completed - Healthy Volunteer Clinical Trials

A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of GDC 0973 in Healthy Subjects

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single-center, open-label, randomized, 3-period, 2-sequence crossover study of GDC-0973 in healthy subjects to evaluate the effect of the proton pump inhibitor (PPI) rabeprazole on the relative bioavailability of GDC-0973 in healthy subjects when administered in the fed or fasted states.

NCT ID: NCT01275157 Completed - Healthy Volunteers Clinical Trials

Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This is a single dose study of radiolabeled [14C]-LY2452473 in healthy male volunteers to study the absorption, distribution, metabolism, and elimination of LY2452473. This study is for research purposes only and is not intended to treat any medical condition.

NCT ID: NCT01273532 Completed - Healthy Volunteer Clinical Trials

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet

Start date: December 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the bioequivalence of a 100-mg tapentadol (CG5503) dose administered as two 50-mg ER, TRF tablets relative to one 100-mg ER TRF tablet in healthy Japanese male participants.

NCT ID: NCT01273506 Completed - Healthy Volunteer Clinical Trials

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet

Start date: December 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the bioequivalence of a 50-mg tapentadol (CG5503) dose administered as two 25-mg ER, TRF tablets relative to one 50-mg ER TRF tablet in healthy Japanese male participants.

NCT ID: NCT01269762 Completed - Healthy Volunteer Clinical Trials

Pharmacokinetic and Drug Interaction Study of Red Yeast Rice Capsules

Start date: January 2011
Phase: Phase 4
Study type: Interventional

Red yeast rice capsule (LipoCol Forte)is a nature product that has been demonstrated a significant cholesterol lowering effect which might be caused by addictive and/or synergistic effects of lovastatin (monacolin K) with other monacolins and substances in capsules. The usual dose of red yeast rice capsule(LipoCol Forte)for hypercholesterolemia is one capsule twice/day. However, the pharmacokinetic profile of red yeast rice capsule (LipoCol Forte)is still unknown. The objective of the study is to evaluate the pharmacokinetic profile of red yeast rice capsule (LipoCol Forte) after administering single and multiple dose to healthy subjects.

NCT ID: NCT01266577 Recruiting - Healthy Volunteer Clinical Trials

Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle

Start date: January 27, 2011
Phase: N/A
Study type: Interventional

Background: - Magnetic resonance imaging (MRI) is a widely used scanning technique to obtain images of the human body and evaluate activity in the brain. A particular MRI method called magnetic resonance spectroscopy (MRS) can be used to study brain chemistry as well, which may help researchers who are studying new treatments for psychiatric illnesses. Researchers are interested in improving current MRI and MRS techniques, as well as developing new MRI and MRS techniques to view and measure brain chemicals and brain activity. Objectives: - To implement, develop, and optimize brain chemistry imaging techniques using magnetic resonance imaging and magnetic resonance spectroscopy. Eligibility: - Healthy individuals between 18 and 65 years of age. Design: - This study will involve a screening visit and a scanning visit at the National Institutes of Health Clinical Center. - Participants will be screened with a full medical and physical examination, blood and urine tests, and neurological testing. - During the second visit, participants will have an MRI scan of the brain. (Participants who have received an MRI within the past year will not need to have a second one; the images of the previous scan will be used for this study.) All participants will then have an MRS scan using the same scanning equipment.

NCT ID: NCT01265108 Completed - Healthy Volunteers Clinical Trials

Effects of Iron on Exercise Capacity During Hypoxia

Start date: November 2010
Phase: Phase 1
Study type: Interventional

During alveolar hypoxia, for example at high altitude or in patients with respiratory disease, there is evidence to suggest that hypoxia-induced pulmonary hypertension might limit exercise performance. Intravenous iron supplementation has recently been shown to reverse pulmonary hypertension in healthy humans at high altitude, and to prevent pulmonary hypertension in volunteers exposed to hypoxia at sea level. The investigators hypothesized that intravenous iron supplementation would enhance exercise capacity during alveolar hypoxia.